Pharmalot By Ed Silverman Doctors Without Borders demands drug makers lower their prices for TB treatments
Politics By Lev Facher and Nicholas Florko Senate committee unveils ambitious plan to cap drug price hikes, out-of-pocket expenses
First Opinion By James R. Baker Jr. EpiPen pricing controversy reflects larger issues in pharma industry
First Opinion By Michael Mandel The ‘prescription escalator’ may be to blame for rising out-of-pocket drug spending
Politics By Lev Facher In a pivotal race in North Carolina, Democrats try to paint the incumbent as ‘pharma’s favorite senator’
Politics By Lev Facher and Nicholas Florko Sensing an advantage, Democrats dare Trump to talk drug prices during State of the Union
Pharmalot By Ed Silverman Pharmalittle: Judge orders pause in suits against Purdue and Sacklers; Teva must face opioid trial
Politics By Lev Facher Former pharma hawk McCaskill: Drug pricing system is a ‘stinking stew of a mess’
Pharmalot By Ed Silverman Pharmalittle: Opioid companies failed to halt suspicious orders; U.K. diabetics are rationing insulin
Politics By Lev Facher Kamala Harris becomes the latest Democratic candidate to zero in on drug prices
Pharmalot By Ed Silverman Pharmalittle: Roche hits milestone with personalized cancer drug; data on a fountain of youth drug
Pharmalot By Ed Silverman Baltimore sues a J&J unit over ‘sham’ patent litigation to extend its monopoly on a cancer drug
Pharmalot By Ed Silverman Generic drug price-fixing suit is akin to earlier case, but ‘on steroids,’ Conn. prosecutor says
Pharmalot By Ed Silverman Seeking to contain drug costs, CMS may have ‘killed’ a PBM billing practice
First Opinion By John Arnold John Arnold: Trump administration’s good effort on drug rebates is bad policy
Pharmalot By Ed Silverman Pharmalittle: A Pfizer and Lilly painkiller misses study goals; LA County joins statewide effort to lower drug prices
Pharmalot By Ed Silverman Vertex CEO says he will bring ‘new ideas’ to break a stalemate in the U.K. over a cystic fibrosis drug
Pharmalot By Ed Silverman The ‘Netflix’ model for hepatitis C drugs is saving Australia a lot of money
Pharmalot By Ed Silverman Lawmakers ask FDA to explain steps to contain contaminants in blood pressure drugs
Pharmalot By Ed Silverman U.K. lawmaker challenges the government to issue a compulsory license for Vertex drug
Pharmalot By Ed Silverman Vertex faces more pressure over pricing, but one analyst does not expect any movement
Pharmalot By Ed Silverman Pharmalittle: AstraZeneca chief medical officer is leaving; a venture capital firm bids farewell to J.P. Morgan
Pharma By Ed Silverman and Matthew Herper Regeneron CEO: ‘We need a carrot-and-stick system’ to balance pricing and innovation
Pharmalot By Ed Silverman Canada ends a probe into three big drug makers accused of thwarting generic competition
Pharmalot By Ed Silverman Trump administration report would preclude reclaiming patents as a way to lower drug prices
Pharmalot By Ed Silverman As pharma seeks more orphan drug designations, FDA fails to assess important needed info